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Patients with ALS show highly correlated
progression rates in left and right limb
muscles
ABSTRACT
Objective: Amyotrophic lateral sclerosis (ALS) progresses at different rates between patients,
making clinical trial design difficult and dependent on large cohorts of patients. Currently, there
are few data showing whether the left and right limbs progress at the same or different rates. This
study addresses rates of decline in specific muscle groups of patients with ALS and assesses
whether there is a relationship between left and right muscles in the same patient, regardless
of overall progression.
Methods: A large cohort of patients was used to assess decline in muscle strength in right and left
limbs over time using 2 different methods: The Tufts Quantitative Neuromuscular Exam and
Accurate Test of Limb Isometric Strength protocol. Then advanced linear regression statistical
methods were applied to assess progression rates in each limb.
Results: This report shows that linearized progression models can predict general slopes of
decline with good accuracy. Critically, the data demonstrate that while overall decline is variable,
there is a high degree of correlation between left and right muscle decline in ALS. This implies that
irrespective of which muscle starts declining soonest or latest, their rates of decline following
onset are more consistent.
Conclusions: First, this study demonstrates a high degree of power when using unilateral treat-
ment approaches to detect a slowing in disease progression in smaller groups of patients, thus
allowing for paired statistical tests. These findings will be useful in transplantation trials that
use muscle decline to track disease progression in ALS. Second, these findings discuss methods,
such as tactical selection of muscle groups, which can improve the power efficiency of all ALS
clinical trials. Neurology® 2017;89:196–206
GLOSSARY
ALS 5 amyotrophic lateral sclerosis; ATLIS 5 Accurate Test of Limb Isometric Strength; GLM 5 generalized linear model;
GLMM 5 generalized linear mixed model; IRB 5 institutional review board; PC 5 principal component; TQNE 5 Tufts
Quantitative Neuromuscular Exam.
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder in which a loss of
motor neurons results in muscle weakness, paralysis, and death within 3–5 years of diagnosis.
There is no successful treatment and the fact that progression rates are different in each patient
makes clinical trial design challenging even when incorporating many patients with ALS into
open source anonymized databases.1,2
One promising cell therapy approach involves the transplantation of stem/progenitor cells
into localized regions of the CNS, permitting new clinical trials where only discreet neuronal
groups are treated.3 Unilateral treatments are expected to affect the side of transplantation
and results can be compared to the nontreated side. This trial design permits the use of more
powerful pairwise statistics, in which measurements are taken side by side at the same time,
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potentially increasing the power of the clinical
trial and alleviating the need for a placebo-
controlled cohort. Critically, this clinical
design requires understanding left and right
limb progression rates. Currently, however,
there are little data showing whether the left
and right limbs progress at the same or differ-
ent rates in the same patient.
The current study analyzed disease progres-
sion in patients with ALS by comparing the
right to left side of muscle pairs and by com-
paring different muscle groups. To do this,
we assessed a large dataset of patients who were
followed over time for muscle strength via fixed
dynamometry using the Tufts Quantitative
Neuromuscular Exam (TQNE).4,5 In addition,
we assessed a set of patients who were followed
using the more recently developed Accurate
Test of Limb Isometric Strength (ATLIS).6
This report shows that linearized progression
models can predict general slopes of decline
with good accuracy. Critically, the data from
patients demonstrate that while overall decline
is variable, there is a high degree of correlation
between left and right muscle decline in ALS.
This study clearly shows that specific muscle
groups may be better to follow in patients over
time due to their consistency in decline rate,
and that most muscles show a very similar rate
of decline between the left and right side of
individual patients with ALS.
METHODS Standard protocol approvals, registrations,
and patient consents. For the TQNE and ATLIS measure-
ments, all participants provided written informed consent as
approved by each site’s institutional review board (IRB) (Massa-
chusetts General Hospital: IRB approval 2013P000702/MGH;
Tufts: Developing a database of the natural history of neuromus-
cular diseases—IRB approval dates 1978–1995 [no number avail-
able]; Cedars-Sinai: IRB approval 38868).
Data collection. A longitudinal, historical database from Tufts
Medical Center consisting of TQNE measurements for 6 mus-
cle groups (hand grip, biceps, triceps, quadriceps, hamstrings,
and anterior tibialis) for each side from 846 patients was ana-
lyzed.4 The data were collected between 1978 and 1995, with
individual participants being typically followed for between 1
and 4 years. However, patients who did not include at least 3
months of data for each muscle were excluded; therefore, only
644 patients were included in all analyses. A cutoff of 1,500
days tracking was applied, as few participants remained present
in the dataset by this point and these participants were outliers.
Additional data for the same muscles were collected using the
newer ATLIS protocol for a smaller cohort of 99 participants.
ATLIS data used El Escorial criteria of definite or probable ALS
diagnosis.
Generalized linear mixed modeling to assess symmetry.
Generalized linear mixed models (GLMM) were used to assess
the trends of decline in each muscle comparing the left and right
side, thus answering the hypothesis of how symmetrical the
decline was for each muscle. See the e-Methods at Neurology.
org for details.
Linear modeling of individual participants. A large matrix
of general linear models, using the same transformations as
applied in linear mixed models previously,7,8 were constructed
for each set of muscles including side of the body, time, and
interactions for each participant. This was used solely to generate
estimates of the rate of decline for each muscle, side, and partic-
ipant for use as measures in principal component (PC) analyses.
PC analyses. PC analysis was performed on the predicted rates
of muscle decline for each participant determined by a matrix of
GLMM against each muscle on each side for every participant.
PCs that contributed less than 9% of the total variance were
excluded. The percentage of variance for each PC was separated
into the contribution to it by each muscle and plotted. Biplots
were used to assess not only the distribution of participants in
each component but also the contribution of each muscle to that
separation. A matrix of vectors was generated representing the
contribution of each muscle by PC, considered variance maps.
These variance maps were then compared using sum of squares
methodology and plotted as a heatmap of strength of similarity
with dendograms. These comparisons were then divided by
descriptive terms and compared.
RESULTS Generalized linear mixed modeling can study
trends in the decline of each pair of muscles. For the
TQNE analysis, the strength of 6 muscle groups, 3
upper (hand grip, biceps, and triceps) and 3 lower
(quadriceps, hamstrings, and anterior tibialis), was as-
sessed on each side of the body for 644 participants
with ALS. The decline in each muscle’s strength
was assessed over time for each participant.
Six GLMMs were produced in order to assess each
pair of muscles and predictions were generated for
each (figure 1, A–F). Measuring predicted muscle
strength score (kN) interestingly showed that the
biceps and hand grip were the only muscles that
had a bias comparing left with right, which may be
explained by right hand dominance. All 4 other pairs
of muscles showed very similar rates of decline com-
paring left vs right sides (table e-1). We also observed
that eachmuscle did on average reach effective paralysis
(kN score of 0) at different relative rates, with paralysis
being earlier in the anterior tibialis (figure 1E) and later
in the quadriceps and triceps (figure 1, A and D). Even
in a very rapidly declining patient and a relatively
slowly declining patient, the similarity between left
and right quadriceps decline within individuals is evi-
dent (figure 1, G and H).
Rate of muscle strength loss is mirrored between the same
muscles in both sides of the body. Generalized linear
models (GLM) were used to generate estimated rates
of decline for all patients in the study for each muscle
on each side. These rates of decline for all 6 muscle
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Figure 1 Generalized linear mixed modeling of Tufts Quantitative Neuromuscular Exam data, comparing left
vs right muscle decline across 6 muscle groups
(A–F) Predictions generated from generalized linear models for muscle decline of each muscle pair (A, quadriceps; B, ham-
strings; C, anterior tibialis; D, biceps; E, triceps; F, hand grip) were plotted (muscle strength against time since first assess-
ment,695% confidence interval). ***Significant differences between left and right (p, 0.001) in the rate of decline. (G, H)
Exemplar plots show examples of extremely rapid (G) and slow (H) declining muscle strength from quadriceps of individual
patients, showing a typically high level of symmetry.
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groups on both sides across participants were used as
individual patient measures for PC analysis (rate of
decline for each muscle on each side), thus allowing
analysis of which differences between muscles best
distinguish participants by variance in the relative
decline of each muscle (figure 2A). This analysis
Figure 2 Principal component (PC) analysis (PCA) of the variability in muscle decline across all participants
The ratesof decline ineachmuscle fromeachpatientwereanalyzedusingPCs. (A)Agraphshows thepercentageof the total varianceexplainedby the first5PCs (those
that representedmore than 9% individually). In addition, the bars on this graph have been subdivided by themodulus of the normalized contributions of eachmuscle to
eachPC. (B) Abar plot represents both themagnitudeanddirection of eachmuscle’s loading in the first5PCs, for both sides. (C)A scatterplot of all participants and their
coordinate in each of the first 5 PCs. (D) A symmetric heatmap represents the sumof squares for comparisons of the variance plots between every pair ofmuscleswith
a dendogram representing the hierarchical levels of similarity between everymuscle. Lower bodymuscles are labeled in red text, upper bodymuscles in blue text. (E) Box
and whisker plots compare meta-groups of muscle comparisons, including same.body, muscles compared that are in the same broad region of the body (upper
or lower); same.muscle, the same muscle compared left vs right; same.side, muscles compared that are on the same side (left or right) of the body; same.side.
body, where the muscle is on the same side (left or right) and same broad region of the body (upper or lower); and those that do not fit any of these categories,
none. (F) Box and whisker diagrams compare different meta-groups of muscle comparisons, defined by whether they are upper or lower body muscles. This
includeswhere an uppermuscle is comparedwith a lowermuscle, a lowermuscle is comparedwith another lowermuscle, and an uppermuscle is comparedwith
another upper muscle. Asterisks indicate statistical significance (*p, 0.05; **p, 0.01; ***p, 0.001) by Bonferroni corrected t test. Muscles abbreviated as
follows: at 5 anterior tibialis; grip 5 hand grip; ham 5 hamstrings; quad 5 quadriceps.
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showed that all of the muscles contributed signifi-
cantly to the first component, implying that the first
component best represents an overall rate of decline
in the participant. This may be due to differences in
slope or the point in disease progression in which the
participant entered the study. To further support this,
we plotted the magnitude and direction of the con-
tribution of each muscle for each of the first 5 PCs
(figure 2B). This plot showed that all of the muscles
were monotonic and similarly contributed to PC-1,
but in contrast the muscles were not monotonic or
similar with respect to PC-2 through 5. This suggests
that PC-1 separates participants by how quickly each
declined over all muscles, where PC-2 through PC-5
concerned differences in how individual muscles were
declining relative to each other. Interestingly, all of
the muscles showed similar contribution in the same
direction when comparing left vs right for the same
muscle in each PC.
One of the considered outcomes of this approach
is that participants may have been roughly categorized
by discreet groups by differential patterns of decline
rate by muscle. Indeed this notion could be consid-
ered consistent with the evidence that patients with
ALS can be loosely categorized by onset in specific
muscle groups. However, studying the positions of
all participants on each PC demonstrated approxi-
mately normal distributions for participants in each
PC, and thus showed that no clusters were forming,
thereby suggesting that distinct populations of partic-
ipants did not exist (figure 2C), at least as could be
separated by these measures. However, different
muscles contribute differently to this linear scale of
variability. Ultimately, it is likely that participants
vary significantly with regard to each muscle, but
do so randomly without clear subdivision into partic-
ulate clusters.
To compare how the relative rates of decline of
each muscle separated participants, a variance against
PC map was produced for each muscle. The maps of
each right and left muscle were compared using a sum
of squares methodology, and each comparison was
plotted on a heat map (figure 2D; upper body shown
in blue, lower body shown in red). Once again, spe-
cific muscles showed closer relationships than others;
the positioning of these muscles on both axes of the
heat map is based on similarity according to a dendo-
gram showing the hierarchy of similarities. In most
cases, this results in left and right muscles sitting
within the lowest and most similar clade of the den-
dogram, and adjacent to each other. This demon-
strates that the same muscle on the opposite side
was generally most similar to each. One exception
was that the biceps and triceps on the same side ex-
hibited closer similarity than left compared to right.
However, in general, the same muscle on opposing
sides showed remarkable consistency, especially in the
case of the quadriceps, triceps, and biceps.
In order to understand which comparisons are
most important, each comparison was categorized
into 5 groups: (1) muscles on the same side of the
body, (2) muscles both of the upper or lower body,
(3) the same muscle on the opposite side of the body,
(4) muscles that are both of the upper or lower body
and on the same side, or (5) none. These categories
were compared by using the sum of the squares, with
lower numbers signifying greater similarity. Results
demonstrated that the same muscle on the opposite
side consistently showed the highest level of similar-
ity, and muscles of the same region showed some sig-
nificance (figure 2E). In addition, the upper body
muscles were significantly closely related, unlike the
lower body muscles (figure 2F).
Finally, comparing the levels of left vs right simi-
larity for the 6 muscles showed that quadriceps had
a unique level of similarity (0.26 sum of squares, com-
pared with average 0.78 6 0.083 [SD]) (figure e-1).
Interestingly, the biceps and triceps had greater sim-
ilarity with each other on opposite sides than when
comparing the same muscle left vs right (left bicep vs
tricep 0.12, right bicep vs tricep 0.6, tricep left vs
right 0.7, and bicep left vs right 0.86).
Different muscles show different relationships between
variability and time. A matrix of GLM was generated
for each patient and each muscle, but separated into
time periods of 100 days in order to assess the rates
of decline in the left and right side and to determine
how consistent this decline was over time. However,
when studying the 100-day time periods indepen-
dently, we found that the rates of decline become
more consistent as the disease progresses in the biceps
and triceps (figure 3A). Further, different muscles
showed different levels of variability over time, with
the biceps and triceps showing lower variability than
the quadriceps or hand grips. The coefficient of var-
iance for each time group was next quantified in order
to assess variability between participants at each time
point, allowing for changing sample size. The triceps
and biceps body show a relatively stable variance
across the time ranges, and to the last time points
(figure 3B). In contrast, the lower body and grip
muscles show a sudden rise in variation in the
,700 time ranges. Collectively, these data are an
important consideration for clinical trial design, espe-
cially a unilateral and sequential clinical trial, as large
increases in variability over time during patient
decline would reduce the power of the experiment.
Finally, the strength and significance of the corre-
lation between rates of decline and time were assessed
in order to determine whether the rates of decline
slow or accelerate over the course of disease
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progression. Correlation tests were subsequently
performed in order to determine the strength of
monotonic relationships (Spearman rank test) and
the strength of linear relationships (Pearson product-
moment test). Only the biceps and hand grip showed
a weak but significant correlation between time and
rate of decline; however, this was likely due to the large
dataset (table e-2). Assessing the correlation between
variability in decline and time showed that there was
a significant negative relationship between variability
and time in all 3 upper body muscles, but not in the
lower body muscles (table e-3), which is consistent
Figure 3 Variability of muscle over time in participants with amyotrophic lateral sclerosis (ALS)
(A) A matrix of plots shows the mean rates of decline for each muscle in participants with ALS for both left and right (blue
and purple, respectively), within 100 days time ranges (post first analysis), and followed by the mean rate of decline for the
participants. The rates of decline were plotted in 10 time periods of 100 days over a 1,000-day period, and the average rate
of decline was plotted fitted across the full 1,000 days. (B) A matrix plot shows coefficients of variance for muscle decline
for each muscle, both left and right (blue and purple, respectively), within 100 days time ranges (post first analysis), and
followed by the overall SD of decline for the participants. Muscles abbreviated as follows: at5 anterior tibialis; grip 5 hand
grip; ham 5 hamstrings; quad 5 quadriceps.
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with figure 4. Curiously, the upper body muscles also
showed a slightly higher correlation between rate of
decline and time (table e-3).
Optimizing the experimental design of clinical trials in
ALS.When designing a clinical trial, it is important to
consider the method of assessment and its potential
for statistical power. In this study, we considered 2
experimental designs that have different purposes
for clinical trials. The first consideration was systemic
or bilateral studies, in which it is typical to monitor
the participant’s rate of decline in a given muscle
for 3–6 months, and then follow the participant for
at least an equal length of time after treatment using
the same muscle (figure 4A). The second experimen-
tal design was unilateral treatments; for example,
transplantation into one side of the spinal column
or brain (figure 4B). Both experimental designs allow
for paired statistical tests, which abrogate certain as-
pects of participant variability. The unilateral test has
the further advantage of allowing for a paired test over
time, which further abrogates time-specific partici-
pant variability. In the bilateral experimental design,
the variance was restricted to the variance in decline
from individual participants.
Using the SDs predicted by GLM, power tests
were performed iteratively for between 2 and 25 par-
ticipants, assuming a 50% change in decline when
treated and a significance level of 0.05. The difference
in power against number of participants is striking
when comparing the 2 methodologies (figure 4, C
vs D). The unilateral approach shows that signifi-
cantly fewer participants were required per group in
order to achieve 80% power at 0.05% CI compared
Figure 4 A comparison of the relationship between power and number of participants for both experimental
designs and for each muscle
(A) A demonstration of a participant where participants were followed for 6months without treatment and then followed for
6 months with treatment, assuming a 50% change in decline with treatment. The green line indicates the mean rate of
decline, the purple line the expected mean decline given a 50% reduction in rate, the solid blue line mock muscle recordings
before treatment, the red line mock muscle recordings after treatment, and the dashed blue line mock muscle recordings
assuming the treatment is ineffective. (B) A demonstration of a participant where participants were followed for 6 months
without treatment and then followed for 6 months with unilateral treatment, assuming a 50% change in decline with treat-
ment. The green line indicates the mean rate of decline, the purple line the expected mean decline given a 50% reduction in
rate, the solid blue line mock muscle recordings for the untreated side, and the red line mock muscle recordings for the trea-
ted side. (C) Power vs number of participants (per group) where participants were followed for 6 months without treatment
and then followed for 6 months with treatment, assuming a 50% change in decline with treatment. (D) Power vs number of
participants (per group) where treatment was unilateral and the participant followed for 6 months, assuming a 50% change
in decline with treatment. Muscles abbreviated as follows: at5 anterior tibialis; grip5 hand grip; ham5 hamstrings; quad5
quadriceps.
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with bilateral treatment (table e-4A). In the unilateral
experimental design, it is not necessary to observe the
participant prior to treatment to determine a baseline,
unless there is an intention to assess both potential
unilateral and bilateral effects of the treatment.
Another interesting observation is the significant
difference in the number of participants needed to
achieve sufficient power in different muscles. The tri-
ceps and biceps performed well with both experimen-
tal designs, requiring 21 and 20 participants per
group in the sequential experimental design, respec-
tively, and 11 and 10 participants per group in the
unilateral experimental design (table e-4A). Interest-
ingly, the quadriceps also performed well under the
unilateral approach (9 participants per group to reach
80% power), but performed relatively poorly under
the sequential approach (27 participants per group
to reach 80% power). This is likely because, although
the quadriceps display a relatively high level of consis-
tency in decline by side, they show higher levels of
variability over time.
To next compare TQNE data with data collected
using a more easily performed method, the ATLIS
system assessed the same 6 muscles longitudinally in
99 participants, with some for over a maximum
period of 600 days. GLMMwere used to assess differ-
ences between left and right as well as variability in
patient decline (figure 5, A–F). In contrast to the
TQNE data, no difference was observed when com-
paring left vs right. However, this is likely due to the
smaller sample size being unable to detect relatively
small differences and the fact that participants were
followed over a shorter period of time.
In order to study the power achievable using the
ATLIS system for clinical trial, we assessed both uni-
lateral and bilateral experimental paradigms, assum-
ing a treatment efficacy of a 50% reduction in
decline rate. Consistent with the TQNE results, AT-
LIS results showed that a greater power could be
achieved using the unilateral treatment option due
to the simultaneous internal control offered by the
other side of the body (figure 5, G vs H). While
the ATLIS data are predicted to perform slightly bet-
ter than the TQNE data using the sequential exper-
imental paradigm, both measurements performed
similarly using the unilateral experimental design
(table e-4B).
DISCUSSION In this study, we examined the differ-
ent aspects of variability in muscle decline across par-
ticipants with ALS. We found that for most of the
muscles analyzed, the left and right sides on average
decline at the same rate. This result is in agreement
with a recent study that assessed Amyotrophic Lateral
Sclerosis Functional Rating Scale–revised scores.9
Unlike this study, however, we assessed quantitative
measures of left and right muscle strength within
individual patients based on TQNE and ATLIS and,
importantly, we used additional analysis including
linear mixed regression modeling and PC analysis.
We observed highly similar rates of decline compar-
ing left and right, but increased starting strength in
both the biceps and grip strength on the right side,
consistent with the idea that participants were more
likely to be right-handed than left-handed. One of the
principal advantages of a longitudinal study is the
ability to solely measure decline rate, despite the ef-
fects of handiness on starting strength. Shorter-term
or cross-sectional studies would be highly susceptible
to this effect; however, we found that several muscles
were significantly less affected as candidates. The new
knowledge that muscle decline in general is a very
accurate measure of disease progression and very
similar between limbs in the same patient will benefit
future clinical trials using unilateral treatment
approaches.
PC analyses demonstrated that rate of decline sys-
tematically represents the greatest variability between
patients, rather than the variability in individual
muscles. This may appear contradictory with clinical
observations that the disease starts in different regions
and spreads.10 However, it implies that irrespective of
which muscle starts declining soonest or latest, their
rates of decline following onset are more consistent.
The subsequent PCs show differing contributions by
each muscle, and sometimes in different directions.
This demonstrates that some variability is specific to
certain muscles, and some muscles are more closely
related than others. A closer analysis yields an approx-
imately normal distribution of patients across all PCs.
This implies that there are no diverging subtypes of
ALS with regards to rates of muscle decline, although
different subtypes are observed with respect to onset
in different muscles. This is consistent with the idea
that ALS spreads from an initial focal point at some
stage during the disease progression, but that once the
disease arrives at the circuit connected to a specific
muscle, it follows a fairly consistent progression and
mechanism.
Unilateral treatment designs are a powerful tool
already used in preclinical studies of ALS and other
degenerative diseases.11,12 Indeed, a unilateral design
has been used in clinical trials for the administration
of growth factors or cells to patients with Parkinson
disease and Huntington disease, and for the administra-
tion of cells to patients with ALS in previous and ongo-
ing clinical trials (clinicaltrials.gov NCT02943850).13–16
Collectively, these studies indicate that a unilateral trial
design could be feasible for stem cell transplantation
studies. This methodology requires the ability to treat
one side or part of the body (animal or human) in iso-
lation to another side or part to be used as an internal
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simultaneous control. A unilateral treatment design gen-
erates a higher power with a lower sample size compared
with bilateral treatment, but is obviously only suitable to
specific treatments.3 A further advantage unique to the
unilateral design is that following a patient for a substan-
tial length of time to measure a pretreatment baseline is
Figure 5 Generalized linear mixed modeling of Accurate Test of Limb Isometric Strength chair data,
comparing left vs right muscle decline across 6 muscle groups, and power curves for speculative
clinical trials
(A–F) Predictions generated from GLM models for muscle decline of each muscle pair (A, quadriceps; B, hamstrings; C,
anterior tibialis; D, biceps; E, triceps; and F, hand grip) were plotted (muscle strength against time since first assessment,
695% confidence interval). ***Significant differences between left and right (p , 0.001) in the rate of decline. (G, H)
Predicted power against sample size plots for bilateral and unilateral clinical trials with a 50% efficacy.
204 Neurology 89 July 11, 2017
not statistically necessary. This is because pairwise sta-
tistics are comparing treated and untreated, which are
measured simultaneously. However, practically speak-
ing, it is likely necessary to track the patient for some
time prior to treatment to assess suitability for the trial.
One potential limitation is that it would be most sus-
ceptible to the effects of initial strength and handiness in
shorter-term studies, but not longitudinal studies mea-
suring rates of decline.
For both designs, the selection of muscles for assay
makes significant differences in the expected statisti-
cal power, and consequently number of participants.
When assaying quadriceps in the unilateral treatment
design, it may be preferable to restrict the analyses to
the earlier stages in disease progression due to the
increased variability in the lower body muscles
towards the end stage. Indeed, the lower body
muscles showed increasing variability over time, most
sharply following 700 days. This trend may be related
to differential use of assistive devices such as wheel-
chairs that can limit the frequency and extent of lower
body muscle use. Furthermore, while the biceps and
triceps performed well under the unilateral experi-
mental design, it should be considered that the right
side balance in the biceps may make this muscle less
suitable than the quadriceps or triceps for a unilateral
trial. Studies have frequently identified grip strength
as showing highly consistent rates of decline and good
correlation with other ALS measures.17 In this study,
we do not suggest otherwise, but we speculate that
ATLIS and TQNE both provide better methods for
consistently measuring strength for other muscles
compared with more routinely used hand-held
dynamometers.
When comparing the ATLIS system data to the
larger TQNE dataset, we again observed a high
degree of similarity in decline when assessing the same
muscle on the left and right, and greater variability
when comparing different muscles. Using the unilat-
eral experimental design, where the untreated side of
the body can serve as an internal control, no apprecia-
ble difference in the predicted power of the TQNE or
ATLIS data was observed. This is consistent with the
rates of decline being highly similar when comparing
left and right.
These analyses demonstrate the importance of
understanding variability in assays used when design-
ing clinical trials, especially in diseases with a complex
progression like ALS. Currently, it would appear that
direct muscle strength assessments are the most effec-
tive assays for ALS progression, being the best com-
promise between ease of use and accuracy.
However, choosing muscles that are least variable
can further reduce the length of assessments and
maintain the highest ratio of power to patients possi-
ble when using direct muscle assays. This study
demonstrates that the biceps and triceps could be very
effective for this purpose in both unilateral and bilat-
eral experimental designs, with the quadriceps being
only slightly better in the unilateral design. New clin-
ical trials are required for ALS in order to develop
a successful treatment, and the knowledge provided
in this report will be critical for designing optimal,
high power future trials.
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